Order Article Reprints

Anobile DP, Bironzo P, Picca F, Lingua MF, Morena D, Righi L, Napoli F, Papotti MG, Pittaro A, Di Nicolantonio F, et al. Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers. 2021; 13(10):2332. https://doi.org/10.3390/cancers13102332

Anobile, Dario P., Paolo Bironzo, Francesca Picca, Marcello F. Lingua, Deborah Morena, Luisella Righi, Francesca Napoli, Mauro G. Papotti, Alessandra Pittaro, Federica Di Nicolantonio, and et al. 2021. "Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma" Cancers 13, no. 10: 2332. https://doi.org/10.3390/cancers13102332

Anobile, D. P., Bironzo, P., Picca, F., Lingua, M. F., Morena, D., Righi, L., Napoli, F., Papotti, M. G., Pittaro, A., Di Nicolantonio, F., Gigliotti, C., Bussolino, F., Comunanza, V., Guerrera, F., Sandri, A., Leo, F., Libener, R., Aviles, P., Novello, S., ... Riganti, C. (2021). Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers, 13(10), 2332. https://doi.org/10.3390/cancers13102332